Abstract:The goal to attenuate inflammation without inducing generalized immunosuppression has focused the attention on chemokines, a family of chemotactic peptides that regulate the leukocyte traffick into tissues. However, the development of drugs that block ckemokine activity may be hampered by the observation that some chemokines display pleiotropic biologic functions. For example, the chemokines CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC exhibit the ability to recruit different leukocytes subsets, the capacity to induce the proliferation of vascular pericytes as well as powerful anti-tumor effects, which are mediated by a common receptor, named CXCR3. Because of their pleiotropic biologic effects, these chemokines have been proposed as possible therapeutic targets in cancer, allograft rejection, glomerulonephritis, diabetes, multiple sclerosis, and autoimmune disorders of the thyroid. The chemokine CXCL4/PF4 shares several activities with CXCL9, CXCL10, and CXCL11, including angiostatic effects, although its specific receptor has remained unknown for a long time. Recently, we provided evidence that the different functions of CXCL9, CXCL10, and CXCL11 on distinct cell types can be at least partly explained by the interaction of these chemokines with two distinct receptors. Indeed, in addition to the classic form of CXCR3 receptor, which we have renamed as CXCR3-A, a novel CXCR3 receptor variant (CXCR3-B) was identified, that not only mediates the angiostatic activity of CXCR3 ligands, but also acts as functional receptor for CXCL4. In this review, we focus on the accumulating evidence demonstrating the pivotal role of CXCR3-binding chemokines in several human diseases. Studies based on CXCR3 targeting have shown its importance in different pathologic conditions and orally active small molecules capable of inhibiting this receptor are now being developed in order to be tested for their activity in humans.

CXCR4: from B-cell development to B cell-mediated diseases

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

CXCR3-binding chemokines: novel multifunctional therapeutic targets

The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases

CXCL13-CXCR5 axis：regulation in inflammatory diseases and cancer

C-X-C Motif Chemokine Receptor 4–Targeted Radioligand Therapy in Hematological Malignancies—Myeloablative Effects, Antilymphoma Activity, and Safety Profile

CXCR4 in Waldenström’s Macroglobulinema: chances and challenges

Chemokine receptors in primary and secondary lymphoid tissues

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia

Involvement of CXCR4 in Normal and Abnormal Development

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

The multiple faces of CXCL12 (SDF-1α) in the regulation of immunity during health and disease

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

Role of CXCR4 in the progression and therapy of acute leukaemia

CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer

The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration

Chemokine Receptor CXCR4: an Important Player Affecting the Molecular-Targeted Drugs Commonly Used in Hematological Malignancies.

The CXCL12 (SDF-1)/CXCR4 Chemokine Axis: Oncogenic Properties, Molecular Targeting, and Synthetic and Natural Product CXCR4 Inhibitors for Cancer Therapy.

Intracellular mediators of CXCR4-dependent signaling in T cells

CXCL13-CXCR5 Axis: Regulation in Inflammatory Diseases and Cancer.

CXCR3-Expressing T Cells in Infections and Autoimmunity